Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$11.7M, or -$71.60 per diluted share. Operating activities generated -$9.5M of cash. At fiscal year end, Shuttle Pharmaceuticals held $10.5M in total assets against $8.2M in total liabilities, including $334,005 of cash and equivalents.
Open the full interactive Shuttle Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Shuttle Pharmaceuticals Key Stats
| Share Price | $5.18 |
|---|---|
| Market Cap | $5.3M |
| 52-Week Range | $2.78 – $39.20 |
| Shares Outstanding | 1.0 million (basic, 2026 Q2) |
Shuttle Pharmaceuticals Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cost of Goods Sold | — | — | $2.1M | $2.4M |
| Gross Profit | — | — | -$2.1M | -$2.4M |
| Operating Income | -$2.6M | -$5.9M | -$7.7M | -$11.9M |
| Pre-Tax Income | -$3.0M | -$6.6M | -$9.1M | -$11.7M |
| Net Income | -$3.0M | -$6.6M | -$9.1M | -$11.7M |
| Diluted EPS | — | -$880.00 | -$825.00 | -$71.60 |
Shuttle Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | -$2.3M | -$2.6M | -$2.2M | -$3.1M |
| Diluted EPS | -$10.50 | -$1.60 | -$4.30 | -$3.10 |
Shuttle Pharmaceuticals Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $8.4M | $2.6M | $1.9M | $334,005 |
| Current Assets | $8.6M | $5.6M | $2.2M | $502,911 |
| Total Assets | $8.7M | $6.0M | $2.5M | $10.5M |
| Current Liabilities | $975,676 | $1.0M | $1.5M | $8.0M |
| Total Liabilities | $975,676 | $1.9M | $1.8M | $8.2M |
| Shareholders' Equity | $7.7M | $4.1M | $709,152 | $2.3M |
Shuttle Pharmaceuticals Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$2.7M | -$5.6M | -$7.3M | -$9.5M |
| Cash From Investing | — | -$2.8M | $2.9M | -$3.1M |
| Cash From Financing | $10.6M | $2.6M | $3.8M | $11.0M |
| Free Cash Flow | — | -$5.6M | -$7.3M | — |
Figures from Shuttle Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Shuttle Pharmaceuticals financials page for every line item.
Shuttle Pharmaceuticals Company Profile
| Ticker | SHPH |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Gaithersburg, Maryland |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001757499 |
Frequently Asked Questions
What was Shuttle Pharmaceuticals' net income in fiscal 2025?
Shuttle Pharmaceuticals reported net income of -$11.7M for fiscal 2025.
What was Shuttle Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Shuttle Pharmaceuticals' diluted EPS was -$71.60 for fiscal 2025 (adjusted for any later stock splits).
How many shares of Shuttle Pharmaceuticals are outstanding?
Shuttle Pharmaceuticals reported a weighted average of 1.0 million basic shares outstanding in 2026 Q2.
What is Shuttle Pharmaceuticals' market cap?
Based on its latest closing price, Shuttle Pharmaceuticals (SHPH) has a market capitalization of about $5.3M.
When does Shuttle Pharmaceuticals' fiscal year end?
Shuttle Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Shuttle Pharmaceuticals headquartered?
Shuttle Pharmaceuticals lists its business address in Gaithersburg, Maryland in its SEC filings.